Future preclinical studies, i.e., using inhibitors of both FTO and ALKBH5 [9], are thus needed to evaluate the role of the ALKBH5 FTO-ATF4 axis in the resistance of cancer cells to treatment. The gene discussed is ATF4; the disease is cancer.